Scribe Therapeutics Inc. Common Stock (SCTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scribe Therapeutics Inc. Common Stock (SCTX) has a cash flow conversion efficiency ratio of 0.032x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.34 Million) by net assets ($-164.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Scribe Therapeutics Inc. Common Stock market cap and net worth for the company's overall valuation and market capitalisation.
Scribe Therapeutics Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Scribe Therapeutics Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Scribe Therapeutics Inc. Common Stock stock price today for real-time trading data and today's change.
Scribe Therapeutics Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scribe Therapeutics Inc. Common Stock ranked by their cash flow conversion efficiency. Review financial agility of Scribe Therapeutics Inc. Common Stock to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
V.S.T Tillers Tractors Limited
NSE:VSTTILLERS
|
0.057x |
|
GDI Integrated
TO:GDI
|
0.066x |
|
SPCG Public Company Limited
BK:SPCG
|
0.013x |
|
Hunan Creator Information Technologies Co Ltd Class A
SHE:300730
|
-0.007x |
|
Y mAbs Therapeutics
NASDAQ:YMAB
|
0.019x |
|
Jw Pharmac
KO:001060
|
0.046x |
|
Shanghai Trendzone Decor Grp
SHG:603030
|
0.052x |
|
Issta Lines Ltd
TA:ISTA
|
0.034x |
Annual Cash Flow Conversion Efficiency for Scribe Therapeutics Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Scribe Therapeutics Inc. Common Stock from 2024 to 2025. Also see Scribe Therapeutics Inc. Common Stock balance sheet assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-143.42 Million | $-45.21 Million | 0.315x | -12.29% |
| 2024-12-31 | $-125.86 Million | $-45.23 Million | 0.359x | -- |
About Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200… Read more